Investigational drug · Phase 3
Rocatinlimab
Also called: AMG 451
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atopic Dermatitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
0 still active
All registered trials
13
Any phase or sponsor naming "Rocatinlimab"
First trial start
2022
May 31, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Rocatinlimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "Rocatinlimab" as an intervention, largest first.
- A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)Pivotal-lookingTerminated
AmgenAmgen (AMGN)
NCT05882877 · 2,621 participants · Start May 31, 2023 · Primary completion Jul 1, 2026
Drug: Rocatinlimab · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 547 sites in all
- A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT05398445 · 769 participants · Start May 31, 2022 · Primary completion Nov 28, 2024
Drug: Rocatinlimab; Placebo · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Anaheim, California · 202 sites in all
- A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT05724199 · 746 participants · Start Feb 21, 2023 · Primary completion Sep 15, 2024
Drug: Rocatinlimab · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Sun City West, Arizona · 234 sites in all
- A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT05651711 · 726 participants · Start Dec 14, 2022 · Primary completion Jun 5, 2024
Drug: Rocatinlimab · For: Atopic Dermatitis
Sites: Litchfield Park, Arizona; Scottsdale, Arizona; Fayetteville, Arkansas · 197 sites in all
- A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT05704738 · 532 participants · Start Apr 20, 2023 · Primary completion Feb 27, 2025
Drug: Rocatinlimab; Placebo · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Cullman, Alabama; Tucson, Arizona · 246 sites in all
- A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo NodularisPivotal-lookingTerminated
AmgenAmgen (AMGN)
NCT06527404 · 469 participants · Start Jul 18, 2024 · Primary completion Apr 17, 2026
Drug: Rocatinlimab; Placebo · For: Prurigo Nodularis
Sites: Birmingham, Alabama; Fountain Valley, California; Los Angeles, California · 192 sites in all
- A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe AsthmaPivotal-lookingTerminated
AmgenAmgen (AMGN)
NCT06376045 · 317 participants · Start May 24, 2024 · Primary completion May 14, 2026
Drug: Rocatinlimab; Placebo · For: Asthma
Sites: Bakersfield, California; La Jolla, California; La Palma, California · 154 sites in all
- A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy ParticipantsPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT06268860 · 240 participants · Start Feb 15, 2024 · Primary completion Aug 30, 2024
Drug: Rocatinlimab vial injection · For: Atopic Dermatitis
Sites: Daytona Beach, Florida; Dallas, Texas; Madison, Wisconsin · 4 sites in all
- A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy ParticipantsPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT06438263 · 231 participants · Start Aug 6, 2024 · Primary completion May 3, 2025
Drug: Rocatinlimab; Rocatinlimab · For: Atopic Dermatitis
Sites: Daytona Beach, Florida; Dallas, Texas; Madison, Wisconsin
- A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT05899816 · 221 participants · Start Jun 7, 2023 · Primary completion Aug 26, 2024
Drug: Rocatinlimab; Placebo · For: Atopic Dermatitis; Moderate-to-severe Atopic Dermatitis
Sites: Scottsdale, Arizona; Tempe, Arizona; Little Rock, Arkansas · 85 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- OX40-OX40L Structural Insights Applied to Rocatinlimab in Atopic Dermatitis With Alopecia Areata Overlap: Mechanistic Hypotheses and Hair Regrowth.
Khan WI, Malik ZZ, Ullah Z, et al. · J Cosmet Dermatol 2026
- Efficacy and Safety of Subcutaneous Rocatinlimab in Adults With Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomised Placebo-Controlled Trials.
Wang HJ, Wang LS, Tan JWL, et al. · Dermatol Res Pract 2026
- Reassessing the OX40/OX40L axis in atopic dermatitis after the termination of Rocatinlimab's clinical development program.
Bieber T · J Eur Acad Dermatol Venereol 2026
- OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders.
Gupta AK, Steriopoulos J, Economopoulos V, et al. · J Eur Acad Dermatol Venereol 2026
- Molecular differentiation of OX40- and OX40L-targeted biologics using AlphaFold3 and molecular dynamics simulations.
Nolden K, Shi Y, Batista VS, et al. · J Invest Dermatol 2026
- Is Kaposi's sarcoma the end of the OX40/OX40L axis in atopic dermatitis?
Salek-Ardakani S · Front Immunol 2026
Also in development for Atopic Dermatitis
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Amgen.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.